Serum miR-27a is a biomarker for the prognosis of non-small cell lung cancer patients receiving chemotherapy

BACKGROUND: Lung cancer has a high incidence and a 5-year survival rate of less than 15%. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases. Chemotherapy and immunotherapy are the most frequently used alternative treatments for patients with advanced-stage NSCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Erfu, Lin, Mingxin, Sun, Ziwei, Jin, Yuexinzi, Zhang, Shichang, Huang, Lei, Sun, Ruihong, Wang, Fang, Pan, Shiyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799153/
https://www.ncbi.nlm.nih.gov/pubmed/35116650
http://dx.doi.org/10.21037/tcr-20-3276

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799153/
https://www.ncbi.nlm.nih.gov/pubmed/35116650
http://dx.doi.org/10.21037/tcr-20-3276

Ejemplares similares